The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives.
Journal
The international journal of neuropsychopharmacology
ISSN: 1469-5111
Titre abrégé: Int J Neuropsychopharmacol
Pays: England
ID NLM: 9815893
Informations de publication
Date de publication:
01 02 2019
01 02 2019
Historique:
received:
05
01
2018
accepted:
05
04
2018
pubmed:
25
4
2018
medline:
28
1
2020
entrez:
25
4
2018
Statut:
ppublish
Résumé
One-third of depressed patients develop treatment-resistant depression with the related sequelae in terms of poor functionality and worse prognosis. Solid evidence suggests that genetic variants are potentially valid predictors of antidepressant efficacy and could be used to provide personalized treatments. The present review summarizes genetic findings of treatment-resistant depression including results from candidate gene studies and genome-wide association studies. The limitations of these approaches are discussed, and suggestions to improve the design of future studies are provided. Most studies used the candidate gene approach, and few genes showed replicated associations with treatment-resistant depression and/or evidence obtained through complementary approaches (e.g., gene expression studies). These genes included GRIK4, BDNF, SLC6A4, and KCNK2, but confirmatory evidence in large cohorts was often lacking. Genome-wide association studies did not identify any genome-wide significant association at variant level, but pathways including genes modulating actin cytoskeleton, neural plasticity, and neurogenesis may be associated with treatment-resistant depression, in line with results obtained by genome-wide association studies of antidepressant response. The improvement of aggregated tests (e.g., polygenic risk scores), possibly using variant/gene prioritization criteria, the increase in the covering of genetic variants, and the incorporation of clinical-demographic predictors of treatment-resistant depression are proposed as possible strategies to improve future pharmacogenomic studies. Genetic biomarkers to identify patients with higher risk of treatment-resistant depression or to guide treatment in these patients are not available yet. Methodological improvements of future studies could lead to the identification of genetic biomarkers with clinical validity.
Sections du résumé
Background
One-third of depressed patients develop treatment-resistant depression with the related sequelae in terms of poor functionality and worse prognosis. Solid evidence suggests that genetic variants are potentially valid predictors of antidepressant efficacy and could be used to provide personalized treatments.
Methods
The present review summarizes genetic findings of treatment-resistant depression including results from candidate gene studies and genome-wide association studies. The limitations of these approaches are discussed, and suggestions to improve the design of future studies are provided.
Results
Most studies used the candidate gene approach, and few genes showed replicated associations with treatment-resistant depression and/or evidence obtained through complementary approaches (e.g., gene expression studies). These genes included GRIK4, BDNF, SLC6A4, and KCNK2, but confirmatory evidence in large cohorts was often lacking. Genome-wide association studies did not identify any genome-wide significant association at variant level, but pathways including genes modulating actin cytoskeleton, neural plasticity, and neurogenesis may be associated with treatment-resistant depression, in line with results obtained by genome-wide association studies of antidepressant response. The improvement of aggregated tests (e.g., polygenic risk scores), possibly using variant/gene prioritization criteria, the increase in the covering of genetic variants, and the incorporation of clinical-demographic predictors of treatment-resistant depression are proposed as possible strategies to improve future pharmacogenomic studies.
Conclusions
Genetic biomarkers to identify patients with higher risk of treatment-resistant depression or to guide treatment in these patients are not available yet. Methodological improvements of future studies could lead to the identification of genetic biomarkers with clinical validity.
Identifiants
pubmed: 29688548
pii: 4980962
doi: 10.1093/ijnp/pyy024
pmc: PMC6368368
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
93-104Références
Eur Neuropsychopharmacol. 2012 Apr;22(4):259-66
pubmed: 21940152
Arch Gen Psychiatry. 2008 Aug;65(8):870-80
pubmed: 18678792
Neuropsychopharmacology. 2017 Mar;42(4):787-800
pubmed: 27510426
Prog Neuropsychopharmacol Biol Psychiatry. 2017 Apr 3;75:128-134
pubmed: 28159590
Acta Neuropsychiatr. 2015 Dec;27(6):353-61
pubmed: 25990886
J Affect Disord. 2015 Oct 1;185:164-9
pubmed: 26186532
Eur Arch Psychiatry Clin Neurosci. 2017 Dec;267(8):723-735
pubmed: 28260126
Neuropharmacology. 2008 Jul;55(1):18-26
pubmed: 18511088
Biol Psychiatry. 2014 Oct 1;76(7):536-41
pubmed: 24529801
Curr Opin Pharmacol. 2006 Feb;6(1):89-97
pubmed: 16361114
Neuron. 2011 Dec 8;72(5):789-805
pubmed: 22153375
J Clin Psychopharmacol. 2010 Apr;30(2):209-11
pubmed: 20520302
Psychopharmacology (Berl). 2014 Feb;231(4):685-93
pubmed: 24114429
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):934-9
pubmed: 20450949
Biol Psychiatry. 2008 Feb 15;63(4):349-52
pubmed: 17643398
Nat Rev Neurosci. 2005 Apr;6(4):267-76
pubmed: 15803158
Neurosci Lett. 2008 May 30;437(2):130-4
pubmed: 18450378
Nat Genet. 2016 Oct;48(10):1279-83
pubmed: 27548312
J Affect Disord. 2014 Mar;156:1-7
pubmed: 24314926
Eur Neuropsychopharmacol. 2012 Apr;22(4):239-58
pubmed: 22137564
Mol Psychiatry. 2016 Apr;21(4):516-22
pubmed: 26122587
Am J Psychiatry. 2010 Jul;167(7):748-51
pubmed: 20595427
Cell Biochem Biophys. 2015 Apr;71(3):1387-93
pubmed: 25388840
Neuropsychopharmacology. 2008 Nov;33(12):2810-9
pubmed: 18288090
Am J Med Genet B Neuropsychiatr Genet. 2010 Jan 5;153B(1):286-90
pubmed: 19309019
Lancet. 2016 Oct 8;388(10053):1545-1602
pubmed: 27733282
J Clin Psychiatry. 2007 Jul;68(7):1062-70
pubmed: 17685743
Psychiatry Res. 2016 Jun 30;240:421-430
pubmed: 27155594
Am J Psychiatry. 2012 Dec;169(12):1238-44
pubmed: 23212054
Pharmacogenomics J. 2014 Oct;14(5):463-72
pubmed: 24709691
J Neurosci. 2003 Sep 3;23(22):8013-9
pubmed: 12954862
Biol Psychiatry. 2012 Dec 1;72(11):e27-8
pubmed: 22771240
Eur Neuropsychopharmacol. 2012 Jul;22(7):453-68
pubmed: 22464339
Nat Neurosci. 2014 Jun;17(6):782-90
pubmed: 24866044
J Psychiatr Res. 2013 Jan;47(1):8-14
pubmed: 23137999
Eur Neuropsychopharmacol. 2015 Apr;25(4):441-53
pubmed: 25769916
Neuropsychopharmacology. 2017 Dec;42(13):2482-2492
pubmed: 28492279
Genet Res (Camb). 2015 Jul 03;97:e14
pubmed: 26139080
Dev Neurobiol. 2010 Nov;70(13):897-911
pubmed: 20669323
Science. 2010 Aug 20;329(5994):959-64
pubmed: 20724638
Transl Psychiatry. 2016 Sep 13;6(9):e889
pubmed: 27622933
Cell. 2017 Jun 15;169(7):1177-1186
pubmed: 28622505
Eur Neuropsychopharmacol. 2017 Sep;27(9):940-944
pubmed: 28648553
J Clin Psychiatry. 2017 Feb;78(2):215-222
pubmed: 28068461
J Neural Transm (Vienna). 2007;114(8):1065-8
pubmed: 17401528
J Neurosci. 2004 May 5;24(18):4401-11
pubmed: 15128854
Neurosci Lett. 2016 Jul 28;626:94-8
pubmed: 27222927
Biol Psychiatry. 2012 Jun 1;71(11):996-1005
pubmed: 22036038
Nat Genet. 2015 Dec;47(12):1385-92
pubmed: 26523775
Am J Psychiatry. 2006 Jan;163(1):28-40
pubmed: 16390886
Neuroreport. 2014 Jul 9;25(10):753-5
pubmed: 24709918
Lancet. 2013 Apr 20;381(9875):1371-1379
pubmed: 23453885
Eur Neuropsychopharmacol. 2011 Jul;21(7):545-62
pubmed: 21168998
Depress Anxiety. 2011 Jul;28(7):568-73
pubmed: 21449006
Am J Psychiatry. 2013 Feb;170(2):207-17
pubmed: 23377640
PLoS Genet. 2014 Apr 10;10(4):e1004269
pubmed: 24721987
PLoS Genet. 2009 May;5(5):e1000477
pubmed: 19492015
Adv Exp Med Biol. 2017;1006:61-82
pubmed: 28865015
Eur Neuropsychopharmacol. 2015 Dec;25(12):2426-36
pubmed: 26441141
Pharmacogenomics J. 2015 Dec;15(6):538-48
pubmed: 25850031
Nat Methods. 2017 Jan;14(1):61-64
pubmed: 27892958
Transl Psychiatry. 2017 Mar 14;7(3):e1061
pubmed: 28291260
BMC Psychiatry. 2016 Apr 18;16:106
pubmed: 27091189
Biol Psychiatry. 2013 Jul 1;74(1):7-14
pubmed: 23380715
Nature. 2004 Oct 21;431(7011):931-45
pubmed: 15496913
Expert Opin Drug Metab Toxicol. 2016 Oct;12(10):1157-68
pubmed: 27310483
Neurosci Lett. 2015 Mar 17;590:116-20
pubmed: 25650523
Neurosci Biobehav Rev. 2018 Jan;84:272-288
pubmed: 28859997
Elife. 2014 Oct 23;3:e03581
pubmed: 25340958
Biol Psychiatry. 2013 Apr 1;73(7):679-82
pubmed: 23237317
J Affect Disord. 2011 Jan;128(1-2):56-63
pubmed: 20643483
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Feb 2;81:203-210
pubmed: 28989100
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jul 1;44:271-8
pubmed: 23537502
J Clin Psychopharmacol. 2011 Aug;31(4):512-6
pubmed: 21694617
Neuroendocrinology. 2015;102(4):274-287
pubmed: 25968351
PLoS Genet. 2016 Dec 30;12(12):e1006493
pubmed: 28036406
Clin Transl Oncol. 2013 Nov;15(11):879-81
pubmed: 23846243